Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ 0.00 (0.00%)

    Theon International

    MCap

    EUR866m

    Last close

    EUR12.36

    ▲ −0.14 (−1.12%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ −0.06 (−12.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Silence Therapeutics

Executive interview – Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines in the increasingly high-profile sector of RNA therapeutics, using the body’s natural mechanism of RNA interference to inhibit the expression of disease. On the back of two recent strategic deals, on 25 March 2020 the company announced a major collaboration with AstraZeneca to develop novel drugs for cardiovascular, renal, metabolic and respiratory diseases. Here to talk through the details of the AstraZeneca deal and equity investment, strategic initiatives and forthcoming milestones for Silence Therapeutics are Dr Rob Quinn, CFO and Dr John Strafford, Head of Business Development.

Silence Therapeutics (SLN) has a portfolio of siRNA drugs in early-stage testing. SLN124 for iron overload is the most advanced and is entering the clinic in Q120. SLN360 is being developed for cardiovascular disease and an IND is planned for H220.

< Previous
Next >

You may also be interested in these:

Investment Companies

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

TMT

IP Group – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free